Search Results
Your search for ,WHo matches 20933 pages
Showing 13051 - 13100Lack of Access to Transfusions Limits Hospice Use by Patients With Hematologic Malignancies
A new survey finds that doctors would refer more patients with incurable blood cancers to hospice for end-of-life care if they could receive transfusions, which are generally not available because of hospice reimbursement policies. The findings, published by Oreofe Odejide, MD, MPH, and colleagues ...
Idelalisib Toxicities Appear to Be Immune-Related
Phosphoinositide 3-kinase (PI3K) inhibitors represent a highly active class of drug for the treatment of chronic lymphocytic leukemia (CLL). Idelalisib (Zydelig), a PI3K-delta inhibitor and the first PI3K inhibitor to be approved by the U.S. Food and Drug Administration (FDA) for CLL, has...
Venetoclax Achieves Durable and Deep Remissions in CLL
Preliminary study results suggest that venetoclax (Venclexta) plus rituximab (Rituxan) is a highly active combination in relapsed/refractory chronic lymphocytic leukemia (CLL), achieving durable responses and minimal residual disease negativity in previously treated patients. “The results of our...
FDA Approves Pembrolizumab for First Tissue/Site-Agnostic Indication
On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed...
Tree Nut Consumption May Improve Outcomes in Stage III Colon Cancer
Tree nut consumption, as well as a generally healthy lifestyle, significantly reduced the risk of cancer recurrence and death in patients with stage III colon cancer treated in the Cancer and Leukemia Group B (CALGB) 89803 trial, researchers reported at the 2017 ASCO Annual Meeting. Two subanalyses ...
ASCO 2017: Ibrutinib Plus Cellular Therapy CTL119 May Lead to Complete Remissions in CLL
Combining the kinase inhibitor ibrutinib (Imbruvica) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University...
Value-Based Decision-Making Tools: The View Ahead
As new treatment decision-making tools make their way toward and into the clinic, oncologists are getting a sense of how they may affect clinical practice—and beginning to look farther down the road. “What do you see ahead for clinicians?” asked Christian Downs, JD, Executive Director of the...
ASCO 2017: Higher Gut Bacteria Diversity Tied to Slower Metastatic Melanoma Progression
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, reported Wargo et al at the 2017 ASCO Annual Meeting (Abstract 3008). Their study of fecal samples from 105 patients treated with...
European Commission Approves Nivolumab for Previously Treated, Locally Advanced, Unresectable or Metastatic Urothelial Cancer
On June 2, the European Commission (EC) approved nivolumab (Opdivo) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. This makes nivolumab the first immuno-oncology agent approved in the European Union ...
Adjuvant Gefitinib Delays Recurrence in EGFR-Positive NSCLC
Adjuvant therapy with gefitinib (Iressa), an epidermal growth factor receptor (EGFR)-targeted agent, was more successful at preventing recurrence than standard-of-care chemotherapy, in a phase III study of patients with EGFR-positive non–small cell lung cancer (NSCLC).1 Gefitinib extended...
ASCO 2017: Adding PEGPH20 to Standard Treatment in Metastatic Pancreatic Cancer May Delay Disease Progression
By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a phase II clinical trial led by an...
ASCO 2017: Many Emergency Department Visits Among Patients With Cancer Appear Preventable
Among patients with cancer, as many as 53% of emergency department visits that do not require admission could be avoided with better symptom management and greater availability of outpatient care tailored to their needs, according to a new study from Fred Hutchinson Cancer...
ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators
ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. “We are very pleased with the...
Effect of Previous Radiotherapy on Outcome With Pembrolizumab in NSCLC
In a single-site experience reported in The Lancet Oncology by Shaverdian et al, patients with advanced non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial of pembrolizumab (Keytruda) were found to have better outcomes if they had received prior radiotherapy. Study Details...
Solange Peters, MD, PhD, and Mary Gospodarowicz, MD, on Mentoring Women in Oncology: An International Perspective
Solange Peters, MD, PhD, of the University of Lausanne, who has been a driving force in ESMO’s efforts to promote women in oncology, talks with Mary Gospodarowicz, MD, of Princess Margaret Hospital, a recipient of the 2017 Women Who Conquer Cancer Mentorship Award.
ASCO 2017: Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non–small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted...
ASCO 2017: Early Research Suggests First Immunotherapy for Mesothelioma on the Horizon
Malignant pleural mesothelioma is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13 to 15 months. All patients relapse despite initial chemotherapy, more than 50% of them within 6 months...
Elizabeth J. Shpall, MD, and Nina Shah, MD—Mentor and Mentee: A Conversation
Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and recipient of the 2017 Women Who Conquer Cancer Mentorship Award, discusses promoting women in oncology with Nina Shah, MD, of the University of California, San Francisco, the protégé who nominated Dr. Shpall for this ...
ASCO 2017: BCMA-Specific CAR T-Cell Therapy Sends Relapsed/Refractory Multiple Myeloma Into Lasting Remission in an Early Trial
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving immunotherapy with chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein, or BCMA. Most patients had only mild side effects. The study was presented by Fan et al...
OlympiAD Trial: Olaparib in Metastatic Breast Cancer With Germline BRCA Mutation
As reported in the Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Robson et al, the phase III OlympiAD trial showed that the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) prolonged progression-free survival vs standard therapy in...
ASCO 2017: The APHINITY Trial: Adding a Second HER2 Blocker May Lower Chance of Invasive Breast Cancer for Some Women
A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests the addition of a second HER2-targeted medicine, pertuzumab (Perjeta), to standard-of-care trastuzumab (Herceptin) after surgery may improve outcomes, although the benefit is modest. The study was presented by von...
Jame Abraham, MD, on Breast Cancer: Expert Perspective on the MONARCH 2 Trial
Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. (Abstract 1000)
ASCO 2017: The IDEA Collaboration: Global Study Sets New Risk-Based Standard to Personalize Chemotherapy for Colon Cancer After Surgery
After surgery for lymph node–positive colon cancer (stage III), some patients may need only half of the long-standing standard course of chemotherapy. In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months in patients with...
ASCO 2017: Web-Based System for Self-Reporting Symptoms Helps Patients Live Longer
A randomized clinical trial of 766 patients shows that a simple intervention—a Web-based tool that enables patients to report their symptoms in real time, triggering alerts to clinicians—can have major benefits, including longer survival. Patients with metastatic cancer who used the...
ASCO 2017: OlympiAD Trial: Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer
Findings from a phase III clinical trial of about 300 women may introduce poly ADP ribose polymerase (PARP) inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced the chance of progression of advanced,...
Erin Van Blarigan, ScD, on Colon Cancer: The Effect of Diet and Exercise, Results From CALGB 89803
Erin Van Blarigan, ScD, of the University of California, San Francisco, discusses the value of lifestyle recommendations from the American Cancer Society for people who have been diagnosed with colon cancer, including longer disease-free and overall survival. (Abstract 10006)
Viviane Hess, MD, on Managing Stress in Newly Diagnosed Patients
Viviane Hess, MD, of the University of Basel and University Hospital Basel, discusses a Web-based stress management tool, called STREAM, designed to reduce stress and improve quality of life for newly diagnosed cancer patients, who often lack psychological support. (Abstract LBA10002)
ASCO 2017: Larotrectinib Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers
Scientists may have developed the first targeted, oral, tumor-type agnostic therapy—an agent that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment...
ASCO 2017: ProfiLER Trial: Routine Genomic Testing Feasible, but Only a Subset of Patients May Benefit
Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing is not yet routine care. A...
ASCO 2017: Pregnancy After Breast Cancer Does Not Increase Chance of Recurrence
Findings from a retrospective study of 1,200 women provide reassurance to breast cancer survivors who are contemplating pregnancy. In the study, women who became pregnant after an early breast cancer diagnosis, including those with estrogen receptor–positive tumors, did not have a higher...
ASCO 2017: LATITUDE Trial: Addition of Abiraterone to Standard Hormonal Therapy Improves Outcomes in Newly Diagnosed Metastatic Prostate Cancer
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer...
ASCO 2017: STAMPEDE Trial: Adding Abiraterone to Standard Treatment Improves Survival in Advanced Prostate Cancer
The STAMPEDE clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone vs 83% with standard...
ASCO 2017: Remote Therapy Program Improves Quality of Life, Lowers Distress After Cancer Diagnosis
Most patients experience significant distress after they are diagnosed with cancer. This distress not only erodes quality of life, but can also negatively affect the course of the disease and the patient’s ability to tolerate treatment. Yet few patients with cancer receive psychological...
ASCO 2017: Single-Dose Radiotherapy as Effective as Multiple Fractions in Relieving Symptoms of Spinal Cord Compression
Spinal cord compression is a common complication in people with metastatic cancer and is a major detriment to quality of life. Radiation treatment is widely used to relieve pain and other symptoms, but there is no standard recommended schedule, and approaches currently vary. Findings from a phase...
ASCO 2017: Low Testosterone Level After Testicular Cancer Is Common, Linked to Chronic Health Problems
In a large study, 38% of 491 testicular cancer survivors had low testosterone levels. Compared with survivors with normal testosterone levels, survivors with low testosterone levels were more likely to have a range of chronic health problems, including high blood pressure, diabetes, erectile...
ASCO 2017: Conquer Fear Intervention Lowers Young Breast Cancer Survivors’ Fear of Cancer Recurrence
About 50% of all cancer survivors and 70% of young breast cancer survivors report a moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life. Yet interventions to alleviate ...
ASCO 2017: Steady Decrease in Severe Health Problems for Childhood Cancer Survivors
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems...
ASCO 2017: CALM Intervention Relieves Distress in Patients With Advanced Cancer
Advanced cancer triggers enormous distress and brings challenges that can seem overwhelming. Yet most cancer centers lack systematic approaches to help patients and families manage the practical and emotional toll of advanced cancer. Findings from a randomized clinical trial of 305 patients with...
Celebrating Cancer Survivorship
Sunday, June 4, 2017, marks the 30th anniversary of National Cancer Survivors Day. Here’s a look at the progress that has been made over the past 2 to 3 decades in reducing cancer incidence and cancer deaths and the challenges that remain. Increasing Rates of Cancer Survivorship In 1971, the...
Spanish Analysis of Prognostic Impact of MRD-Negative Status in Multiple Myeloma
A pooled analysis of three PETHEMA/GEM studies has shown that minimum residual disease (MRD)-negative status after induction therapy is more prognostic of favorable outcome than complete response alone in newly diagnosed multiple myeloma. The findings were reported by Lahuerta et al in the Journal...
Japanese Phase III Trial of Alectinib vs Crizotinib in ALK-Positive NSCLC
The Japanese phase III J-ALEX trial has shown improved progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in ALK inhibitor–naive patients with ALK-positive non–small-cell lung cancer (NSCLC). Results were reported by Hida et al in The Lancet. Study Details In...
Image-Guided Biopsies Accurately Identify Patients With Breast Cancer Who Achieve Pathologic Complete Response Following Neoadjuvant Therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response after neoadjuvant systemic therapy consisting of chemotherapy and/or targeted therapy. Should the...
Study Finds Hypofractionated Whole-Breast Irradiation Leads Breast Cancer Radiation Therapies in Cost-Effectiveness, Quality of Life
In a study of three radiation therapies for early-stage breast cancer, one treatment option stands out as offering the most value based on factors including health outcomes, cost-effectiveness, and quality of life. The treatment—hypofractionated whole-breast irradiation—also requires...
Breast Cancer Risk and Histologic Findings in Serial Benign Biopsies
As reported by Visscher et al in the Journal of the National Cancer Institute, changes in the histologic category between initial and subsequent biopsies had a significant effect on the risk for breast cancer among women with serial benign biopsy findings. Study Details The study involved 1,414...
FDA Broadens Ceritinib Indication to Previously Untreated ALK-Positive Metastatic NSCLC
On May 26, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to ceritinib (Zykadia) for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In April 2014,...
After Nearly 4 Decades of Research, W.K. Alfred Yung, MD, Sees a New Era Ahead for Advances in Brain Tumors
After he was not accepted into the University of Hong Kong, plan B for W.K. Alfred Yung, MD, was to leave his country and immigrate to the United States to attend the University of Minnesota in Minneapolis—a move he considers more exile than choice. Born on April 8, 1948, in Hong Kong, Dr. Yung...
AACR Honors Mina J. Bissell, PhD, FAACR, With Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) recognized Mina J. Bissell, PhD, FAACR, with the 14th AACR Award for Lifetime Achievement in Cancer Research during the 2017 AACR Annual Meeting in Washington, DC. The AACR Award for Lifetime Achievement in Cancer Research was established in 2004 ...
Leader in International Clinical Trials, Robert L. Comis, MD, FASCO, Dies at 71
Robert L. Comis, MD, FASCO, Co-Chair of the ECOG-ACRIN Cancer Research Group, succumbed to a sudden illness at his home and died on May 10, 2017, at the age of 71. A giant in national and international clinical research since 1977, Dr. Comis is known as a champion of patient access to cancer...
For Eric P. Winer, MD, Empathy and a Sense of Purpose Lead to a Career in Oncology
Eric Paul Winer, MD, was born in Boston in 1956, a year when gasoline was 22 cents a gallon and IBM released the world’s first computer with a hard drive. His grandfather on his mother’s side had hemophilia and died 5 years before Dr. Winer was born. Although there was a 50% chance that Dr. Winer...
Conquer Cancer Foundation of ASCO Awards Celebrate Innovation and Diversity
The Conquer Cancer Foundation of ASCO (CCF) is proud to recognize the recipients of its 2017 CCF Merit Awards and its Diversity Awards, which include the Medical Student Rotation Award for Underrepresented Populations and the Resident Travel Award for Underrepresented Populations. Geared toward...
